Hong Kong-listed Insilico Medicine says it has entered a collaboration with US-based Human Longevity to co-develop large-scale artificial intelligence “foundation models” intended to predict diseases decades before symptoms appear. The companies describe the effort as a major step in applying AI to human longevity, with an emphasis on early disease detection through long-range forecasting. Insilico is a drug-discovery company that uses machine-learning approaches to identify and develop potential treatments, and it is positioning this partnership as part of a broader push to extend healthy lifespan. Bloomberg reports Insilico is “tapping” a US partner as it expands its work toward longevity-focused AI models. The South China Morning Post adds more detail on the companies’ stated goal, including predicting conditions such as cancer ahead of clinical onset. Both outlets frame the collaboration as an effort to build advanced, large-scale AI models for longevity and disease prediction. The announcements also connect the project to growing market demand driven by population ageing and increased focus on long-term health.